The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.

[1]  J. McCubrey,et al.  Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). , 2003, International journal of oncology.

[2]  G. Feuerstein,et al.  Significant Neuroprotection against Ischemic Brain Injury by Inhibition of the MEK1 Protein Kinase in Mice: Exploration of Potential Mechanism Associated with Apoptosis , 2003, Journal of Pharmacology and Experimental Therapeutics.

[3]  D. Strumberg,et al.  The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer , 2002, Oncology Research and Treatment.

[4]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[5]  M. Moskowitz,et al.  Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[7]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[8]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[9]  A. Reith,et al.  Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. , 2000, Brain research. Molecular brain research.

[10]  John C. Lee,et al.  p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. , 2001, Progress in medicinal chemistry.

[11]  J. Boehm,et al.  Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. , 1997, Bioorganic & medicinal chemistry.